(Q40158643)

English

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract

scientific article published on 20 February 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

respiratory syncytial virus

0 references

0 references

6

object named as

Nita K Patel

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

9

object named as

Peter A Kiener

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1

object named as

Herren Wu

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

author name string

David S Pfarr

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Syd Johnson

3

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Yambasu A Brewah

4

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Robert M Woods

5

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Wendy I White

7

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

James F Young

8

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

language of work or name

0 references

publication date

20 February 2007

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Journal of Molecular Biology

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

368

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

652-665

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Animal models of respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Tailor-made antibody therapeutics

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Respiratory infections: their role in airway responsiveness and the pathogenesis of asthma

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview.

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Progress in defining the role of RSV in allergy and asthma: from clinical observations to animal models

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Immunization of cotton rats with the human respiratory syncytial virus F glycoprotein produced using a baculovirus vector

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Mortality associated with influenza and respiratory syncytial virus in the United States

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection.

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Treatment of Respiratory Syncytial Virus Bronchiolitis and Pneumonia in a Cotton Rat Model with Systemically Administered Monoclonal Antibody (Palivizumab) and Glucocorticosteroid

1 reference

https://api.crossref.org/works/10.1016/J.JMB.2007.02.024

29 December 2022

Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD000181.PUB2

Identifiers

10.1016/J.JMB.2007.02.024

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

release_5wxbkwej2bdoro6xz6zilqlkzi

1 reference

https://api.fatcat.wiki/v0/release/5wxbkwej2bdoro6xz6zilqlkzi

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40158643&oldid=2040531408"